新興国(ブラジル/インド/南アフリカ)のオピオイド(Opioids)市場

◆英語タイトル:Opioids Market Overview to 2023 - Opioids in Emerging Markets
◆商品コード:GBI054CBR
◆発行会社(リサーチ会社):CBR Pharma Insights
◆発行日:2014年11月30日
◆ページ数:72
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,995 ⇒換算¥311,480見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,990 ⇒換算¥622,960見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD8,985 ⇒換算¥934,440見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はCBR Pharma Insights社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
CBR Pharma Insights社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Opioids Market Overview to 2023 – Opioids in Emerging Markets

Summary

The report provides analysis of new developments that will have a strong bearing on the use of opioids in pain management in emerging countries (Argentina, Brazil, China, India, Mexico, Russia and South Africa). Access to opioids is restricted under strict drug control policies and regulations overseeing controlled medicines due to their high abuse potential. Emphasis on restricting access to controlled drugs is much higher in emerging markets than in developed nations, resulting in a level of consumption that is too low to meet pain-control requirements even in cases of terminal illness. There is a high level of unmet need for pain control in both cancer and HIV/AIDS, and serious concerns have been raised regarding inadequate pain management in the emerging markets.

However, this is expected to change in the near future as regulatory authorities attempt to remedy the situation. Indeed, several new developments promise a better outlook for future access. Although India currently has a minor share of the market, it is expected to post a high growth rate (21.3% by 2023) due to improved access to opioid analgesics. Similarly, consumption in Brazil and Argentina is also expected to increase due to recent changes to their palliative care policies. Although the opioids market in emerging countries is small, it is expected to grow at a faster pace in forecast period than in some developed countries.

Scope

“Opioids in Emerging Markets covers” the major emerging markets of Argentina, Brazil, China, India, Mexico, Russia, and South Africa, and includes –
- Discussion of the key challenges that restrict opioid use in pain management
- Analysis of the inadequate use of opioids in pain control and the associated unmet need
- Discussion of the key changes in the regulatory and legal landscape that affect opioids, prescription barriers, palliative care, and harm-reduction activities
- Analysis of recent developments in emerging markets and their expected impact on opioid accessibility and usage
- Country snapshots, which include key regulations, consumption, market revenues and forecasts, and key drivers and barriers in India, Brazil and South Africa
- Snapshot of consumption trends along with market revenues and forecasts in Argentina and China

Key Reasons to Purchase

- Understand the key constraints in emerging markets that limit the use of opioids in pain management
- Understand recent changes in the regulatory environment and gauge their impact on opioid usage
- Gain perspective on the unmet need in the opioids market
- Understand the market size and growth potential in emerging markets and identify high-potential countries for opioid products

【レポートの目次】

Executive summary
Opioids in pain management
Opioids in emerging markets: an overview
Low utilization of opioids
Changing regulatory landscape
Key challenges and barriers in emerging markets
Factors affecting opioid usage
Highly restricted environment
Criminalization of drug use
Lack of palliative care
Lack of harm-reduction strategies
Opioid consumption in emerging markets
Country snapshots (Brazil, India and South Africa)
Regulatory landscape
Consumption trends
Volume and revenue by molecule
Barriers and activities to rationalize usage
Appendix
Abbreviations/acronyms
References





【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[新興国(ブラジル/インド/南アフリカ)のオピオイド(Opioids)市場]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆